Can we stop diazepam abruptly and start eszopiclone (Lunesta) in a patient with insomnia who is taking diazepam 5 mg daily plus a PRN bedtime dose?

Diazepam Tapering and Transition to Eszopiclone

Direct Answer

You cannot abruptly stop diazepam when starting eszopiclone (Lunesta)—the diazepam must be gradually tapered over several weeks to months while initiating cognitive behavioral therapy for insomnia (CBT-I) alongside the new medication. 1, 2

---

Why Abrupt Discontinuation Is Dangerous

• Diazepam has a long elimination half-life (20-100 hours) and active metabolites that accumulate with chronic use, making abrupt cessation particularly hazardous. 1
• Sudden benzodiazepine discontinuation produces withdrawal symptoms including rebound insomnia (worsening of symptoms lasting 1-3 days), anxiety, tremor, seizures, and potentially life-threatening complications. 1
• Rebound insomnia occurs in nearly all patients who stop benzodiazepines abruptly after more than a few days of use, and can be severe enough to drive patients back to the medication. 1

---

Evidence-Based Tapering Protocol

Tapering Schedule

• Reduce diazepam dose by 10-25% each week, using the smallest possible decrement at each step. 2
• Each dose reduction should be maintained for at least several days (ideally 1 week) before the next reduction. 1
• For a patient taking 5 mg daily plus 5 mg PRN (total 10 mg/day if using PRN nightly), the taper will require 4-10 weeks minimum. 1, 2

Specific Tapering Strategy

• Week 1-2: Reduce total daily dose to 7.5 mg (e.g., 5 mg scheduled + 2.5 mg PRN, or 3.75 mg twice daily). 1, 2
• Week 3-4: Reduce to 5 mg total daily (e.g., 2.5 mg twice daily or 5 mg once daily). 1, 2
• Week 5-6: Reduce to 2.5 mg daily. 1, 2
• Week 7-8: Reduce to 1.25 mg daily, then discontinue. 1, 2
• Alternative approach: Taper the frequency (every other night, then every third night) rather than dose, which also minimizes rebound effects. 1

---

When to Start Eszopiclone

• Begin eszopiclone 2 mg at bedtime on the same night you start the diazepam taper—do not wait until diazepam is fully discontinued. 3, 2
• This cross-taper approach maintains sleep support while gradually withdrawing the benzodiazepine, and is explicitly recommended by European consensus guidelines. 2
• Eszopiclone has been shown to facilitate gradual discontinuation of benzodiazepines and Z-drugs within a cross-tapered program. 2

Eszopiclone Dosing

• Start with 2 mg at bedtime for non-elderly adults; this dose addresses both sleep onset and maintenance. 3, 4, 5
• If sleep maintenance remains problematic after 1-2 weeks, increase to 3 mg, which is more effective for staying asleep throughout the night. 3, 4
• For elderly or debilitated patients, start with 1 mg and do not exceed 2 mg. 3

---

Mandatory Concurrent CBT-I

• The American Academy of Sleep Medicine mandates that all patients with chronic insomnia receive CBT-I as the initial treatment before or alongside any pharmacotherapy—this is non-negotiable. 1, 3
• CBT-I includes stimulus control therapy (only use bed for sleep/sex, leave bedroom if not asleep within 20 minutes), sleep restriction therapy (limit time in bed to actual sleep time plus 30 minutes), relaxation techniques, and cognitive restructuring of negative thoughts about sleep. 1, 3
• CBT-I demonstrates superior long-term outcomes compared to medications alone, with sustained benefits after medication discontinuation, and significantly increases the success rate of benzodiazepine tapering. 1, 3, 2
• Tapering and discontinuation of hypnotic medication is facilitated by concurrent application of cognitive-behavioral therapies, which increase rates of successful discontinuation and duration of abstinence. 1

---

Critical Safety Monitoring During Transition

Weeks 1-2

• Assess for withdrawal symptoms: anxiety, tremor, sweating, palpitations, insomnia worsening, irritability. 1
• Evaluate eszopiclone tolerability: unpleasant taste (most common side effect), headache, dizziness, morning sedation. 4, 5
• Screen for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating) which require immediate discontinuation of eszopiclone. 3

Weeks 3-8

• Monitor sleep parameters: sleep onset latency, wake after sleep onset, total sleep time, number of awakenings. 1, 3
• Assess daytime functioning: alertness, cognitive performance, mood, quality of life. 3, 5
• If withdrawal symptoms emerge, slow the taper by maintaining the current dose for an additional 1-2 weeks before the next reduction. 1

---

Why Eszopiclone Is Appropriate for This Transition

• Eszopiclone is a first-line benzodiazepine receptor agonist (BzRA) recommended by the American Academy of Sleep Medicine for both sleep onset and sleep maintenance insomnia. 3
• Unlike diazepam, eszopiclone has a shorter half-life (6 hours) with no active metabolites, resulting in minimal next-day residual effects and no drug accumulation. 6, 7, 5
• Eszopiclone is the only hypnotic not restricted to short-term use in its FDA labeling, making it suitable for patients requiring longer treatment during benzodiazepine withdrawal. 4, 5
• Clinical trials up to 12 months show no evidence of tolerance development with eszopiclone, and discontinuation produces no rebound insomnia or serious withdrawal effects—a stark contrast to benzodiazepines. 6, 5
• Eszopiclone has been specifically studied and shown effective in facilitating benzodiazepine discontinuation within cross-taper protocols. 2

---

Common Pitfalls to Avoid

• Never stop diazepam abruptly—this is the most dangerous error and can precipitate severe withdrawal including seizures. 1
• Do not wait until diazepam is fully tapered before starting eszopiclone—begin the cross-taper immediately to maintain sleep support. 2
• Avoid tapering too quickly (>25% per week)—this increases withdrawal symptoms and taper failure rates. 1, 2
• Do not prescribe eszopiclone without initiating CBT-I—pharmacotherapy alone has inferior long-term outcomes and higher relapse rates after discontinuation. 1, 3
• Never combine eszopiclone with alcohol or other CNS depressants during the taper, as this increases risk of respiratory depression and complex sleep behaviors. 3
• Do not assume the patient can manage the taper independently—weekly or biweekly follow-up is essential during the first month. 1, 3

---

Special Considerations

If Patient Has Been on Diazepam Long-Term (>6 months)

• Extend the taper to 3-6 months with even smaller dose reductions (10% every 1-2 weeks) to minimize withdrawal severity. 1
• Consider switching to an equivalent dose of a shorter-acting benzodiazepine (e.g., lorazepam) before tapering, though this adds complexity and is not always necessary. 1

If Patient Is Elderly (≥65 years)

• Start eszopiclone at 1 mg (not 2 mg) and do not exceed 2 mg due to increased sensitivity and fall risk. 3
• Taper diazepam even more slowly (10% every 2 weeks) as elderly patients have prolonged elimination and higher withdrawal risk. 1

If Taper Fails

• If withdrawal symptoms are intolerable despite slowing the taper, return to the previous stable dose and maintain for 2-4 weeks before attempting a slower reduction. 1
• Intensify CBT-I delivery (consider individual therapy vs. self-help if not already doing so) to provide additional non-pharmacologic support. 1, 3
• Consider adding low-dose doxepin 3-6 mg instead of eszopiclone if the patient has significant anxiety about medication changes, as doxepin has no abuse potential and works through a different mechanism. 3